Sun Pharmaceutical Industries Inc. Sustainability Profile
Sun Pharmaceutical Industries Inc., commonly referred to as Sun Pharma, is a leading global pharmaceutical company headquartered in the United States. Founded in 1993, Sun Pharma has established a strong presence in various operational regions, including North America, Europe, and Asia, focusing on the development and manufacturing of a diverse range of pharmaceutical products. Specialising in generic and specialty medications, Sun Pharma is renowned for its innovative formulations and high-quality standards. The company’s core offerings include treatments in areas such as psychiatry, neurology, cardiology, and dermatology, setting it apart with a commitment to research and development. With a robust market position, Sun Pharma has achieved significant milestones, including numerous product approvals and a growing portfolio of over 200 generic products. Its dedication to improving patient outcomes and expanding access to essential medications underscores its reputation as a trusted leader in the pharmaceutical industry.
DitchCarbon Score
How does Sun Pharmaceutical Industries Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sun Pharmaceutical Industries Inc.'s score of 59 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sun Pharmaceutical Industries Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Sun Pharmaceutical Industries Limited, which may influence its climate commitments and emissions reporting. As of now, there are no documented reduction targets or climate pledges from Sun Pharmaceutical Industries Inc. However, emissions data and performance metrics may be inherited from its parent company, Sun Pharmaceutical Industries Limited, which operates under the guidance of various sustainability initiatives, including the Carbon Disclosure Project (CDP). The emissions data cascaded from Sun Pharmaceutical Industries Limited may provide insights into the broader corporate climate strategy, although specific figures are not disclosed. In the absence of direct emissions data and reduction targets, it is essential to monitor the company's future commitments and initiatives to understand its role in addressing climate change and reducing carbon emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 77,616,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 377,728,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 |
How Carbon Intensive is Sun Pharmaceutical Industries Inc.'s Industry?
How Carbon Intensive is Sun Pharmaceutical Industries Inc.'s Location?
Sun Pharmaceutical Industries Inc.'s Scope 3 Categories Breakdown
Sun Pharmaceutical Industries Inc.'s Scope 3 emissions, which increased by 6% last year and increased by approximately 6% since 2023, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 51% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 62% of Scope 3 emissions.
Top Scope 3 Categories
Sun Pharmaceutical Industries Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sun Pharmaceutical Industries Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
